医学
紫杉烷
肿瘤科
三阴性乳腺癌
蒽环类
乳腺癌
内科学
杜瓦卢马布
新辅助治疗
癌症
免疫疗法
无容量
作者
Sibylle Loibl,M. Untch,Nicole Burchardi,Jens Huober,Brigitte Sinn,Jens U. Blohmer,E.-M. Grischke,Jenny Furlanetto,Hans Tesch,Claus Hanusch,K. Engels,Mahdi Rezai,Christian Jackisch,Wolfgang Schmitt,G von Minckwitz,Joerg Thomalla,Sherko Kümmel,Beate Rautenberg,Peter A. Fasching,Karsten E. Weber,Kerstin Rhiem,Carsten Denkert,Andreas Schneeweiß
标识
DOI:10.1016/j.annonc.2022.04.003
摘要
The authors regret that in the original publication Fig. 3 was incorrectly presented. The correct figure is as below.The following corrections were made:-In figure 3A, part “additional TIL parameters”, box “iTILs postTx”: The number of patients was N=82 (not N=84 as published).-In figure 3B, row “Durvalumab-arm, sTILs preTx”, column “OR”: The estimated odds ratio was 1.29 (not 1.23 as published). This correction also affects the graphical representation left to column “OR”: The diamond marker must be in the center of the line. The authors regret that in the original publication Fig. 3 was incorrectly presented. The correct figure is as below. The following corrections were made:-In figure 3A, part “additional TIL parameters”, box “iTILs postTx”: The number of patients was N=82 (not N=84 as published).-In figure 3B, row “Durvalumab-arm, sTILs preTx”, column “OR”: The estimated odds ratio was 1.29 (not 1.23 as published). This correction also affects the graphical representation left to column “OR”: The diamond marker must be in the center of the line. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyAnnals of OncologyVol. 30Issue 8PreviewCombining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. Full-Text PDF Open Archive
科研通智能强力驱动
Strongly Powered by AbleSci AI